Definitive Contract HDTRA118C0001
Award Date
12/15/17
Potential Completion Date
12/14/20
Potential Value
$2.6M
Funding Federal Agency
Defense Threat Reduction Agency
Contracting Federal Agency
Defense Contract Management Agency
Awardee
Microbiotix, Inc.
Ultimate Awardee
Not listed
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
Worcester, MA 01605, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
92
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
<p>This is a Phase II Small Business Innovation Research (SBIR) contract awarded by the Defense Threat Reduction Agency (DTRA), a defense agency, to Biofactura Inc., a small business manufacturer, for the process development and manufacture of an antibody-based therapy against Marburgvirus. The contract is a Firm Fixed Price Definitive Contract with a ceiling value of $999,398.93 and a period of performance ending on September 14, 2022. The contract is set aside for small businesses.</p>
This is a $1,140,081.00 Small Business Innovation Research (STTR) Phase II contract awarded by the Defense Threat Reduction Agency to Biological Mimetics, Inc., a biotechnology company that combines biology and engineering to identify and prevent global infections. The contract is for research and development services related to infectious diseases, vaccines, diagnostics, and therapeutics. Biological Mimetics has previously received grants and contracts from federal agencies like the National...
The Defense Threat Reduction Agency awarded a definitive cost-no-fee contract valued at $4,871,862.22 to Massachusetts General Hospital Research Management Division, a subsidiary of Partners Healthcare System Incorporated. The contract is for research to break the code of humoral correlates of protection against Ebola virus and will be performed in Boston, MA from December 2021 through June 2025. Key subcontracts were issued to the La Jolla Institute For Immunology, The Washington University...
This is a $4,440,253.00 definitive federal contract awarded by the Defense Threat Reduction Agency (DTRA) to the University of Texas Medical Branch at Galveston (UTMB) for "QUANTITATIVE DOSE EBOLA" research. The contract has no set-aside designation. UTMB, a state government entity and educational institution, has extensive experience supporting federal agencies in infectious disease research, medical countermeasure development, and biosafety training. The contract provides funding for...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the Department of the Army Medical Command to Biofactura Inc., a for-profit manufacturer, to develop a process for producing an antibody-based therapy against the Marburg virus. The contract has a firm fixed price of $149,528.62 and a completion date of January 15, 2019. The contract is set aside for a small business. This SBIR Phase I award is part of the Army's efforts to advance medical countermeasures against...
This $18,274,778 definitive contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to AN2 Therapeutics, Inc. The contract supports the development of epetraborole as a novel therapeutic for melioidosis and additional antimicrobial resistant bacterial biothreat pathogens. This award was issued under a Broad Agency Announcement (BAA) that also sought proposals for advanced vaccine and diagnostic development against biodefense and emerging...
This is a delivery order awarded under the Homeland Defense and Security Technical Area Tasks (HD TATs) IDIQ contract, issued by the U.S. Air Force Materiel Command. The $5,256,015.00 contract was awarded to Battelle Memorial Institute, a non-profit research and development organization, to provide Ebola diagnostics, field analytics, and sequencing support for the Joint Product Manager Medical Countermeasure Systems. Luminex Corporation, a manufacturer of biological testing technologies, was...
This federal contract award, valued at $73,343,960.25, was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Leidos Biomedical Research Inc. The contract supports research on the Ebola virus and other infectious diseases. The scope of work includes but is not limited to strategic and operational planning, infrastructure operations and maintenance, logistics and procurement management, clinical research protocol...
This is a $1,403,362,669.10 cost-plus-fixed-fee contract awarded by the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response to Emergent Product Development Gaithersburg Inc., a for-profit limited liability company manufacturing medical countermeasures and pharmaceuticals. The contract, which has a period of performance through September 29, 2026, is for the development of filovirus treatments. Emergent has received over $1.3...
This is a $149,747,956.00 federal contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to the Albert B. Sabin Vaccine Institute, Inc. to advance the development of monovalent vaccines for the prevention of Marburg virus (MARV) and Sudan ebolavirus (SUDV) disease. The contract was awarded in September 2019 and has an ultimate completion date of September 30, 2026. This contract was awarded as a Definitive Contract under a Cost No Fee pricing type, with no...